[go: up one dir, main page]

ATE374785T1 - Gpib-gebundenes konstrukt und verwendungen davon - Google Patents

Gpib-gebundenes konstrukt und verwendungen davon

Info

Publication number
ATE374785T1
ATE374785T1 AT01908262T AT01908262T ATE374785T1 AT E374785 T1 ATE374785 T1 AT E374785T1 AT 01908262 T AT01908262 T AT 01908262T AT 01908262 T AT01908262 T AT 01908262T AT E374785 T1 ATE374785 T1 AT E374785T1
Authority
AT
Austria
Prior art keywords
gpib
present
lipid
lipid complex
conjugate
Prior art date
Application number
AT01908262T
Other languages
English (en)
Inventor
Yasuo Ikeda
Hiroshi Saito
Hiromichi Mukai
Yoshiyuki Mori
Mitsuru Murata
Original Assignee
Mitsubishi Pharma Corp
Yasuo Ikeda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp, Yasuo Ikeda filed Critical Mitsubishi Pharma Corp
Application granted granted Critical
Publication of ATE374785T1 publication Critical patent/ATE374785T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Peptides Or Proteins (AREA)
AT01908262T 2000-03-02 2001-03-02 Gpib-gebundenes konstrukt und verwendungen davon ATE374785T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000057449 2000-03-02

Publications (1)

Publication Number Publication Date
ATE374785T1 true ATE374785T1 (de) 2007-10-15

Family

ID=18578236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01908262T ATE374785T1 (de) 2000-03-02 2001-03-02 Gpib-gebundenes konstrukt und verwendungen davon

Country Status (7)

Country Link
US (1) US6926884B2 (de)
EP (1) EP1262490B1 (de)
AT (1) ATE374785T1 (de)
AU (1) AU2001236062A1 (de)
DE (1) DE60130741T2 (de)
ES (1) ES2291295T3 (de)
WO (1) WO2001064743A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1173600A2 (de) * 1999-04-20 2002-01-23 The University Of British Columbia Kationische peg-lipide und verfahren zu ihrer verwendung
US7459169B2 (en) * 2002-10-21 2008-12-02 Allvivo, Inc. Surface coating comprising bioactive compound
KR101197500B1 (ko) * 2002-11-15 2012-11-09 니프로 가부시키가이샤 리포솜
WO2004069862A1 (ja) * 2003-02-06 2004-08-19 Keio University ペプチド結合体
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP5216219B2 (ja) * 2006-01-06 2013-06-19 真司 武岡 薬物運搬体
CN101389356B (zh) * 2006-01-06 2012-09-05 武冈真司 药物输送物质
US20080015145A1 (en) * 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
CA2600220C (en) * 2006-09-07 2014-12-09 Canadian Blood Services Surface cross-linked lipidic particles, methods of production and uses therefor
US20080241233A1 (en) * 2007-03-28 2008-10-02 Portola Pharmaceuticals, Inc. Targeted delivery and expression of procoagulant hemostatic activity
CN109996809A (zh) 2016-11-14 2019-07-09 诺华股份有限公司 与促融合蛋白minion相关的组合物、方法和治疗用途
WO2020080495A1 (ja) 2018-10-17 2020-04-23 東レ株式会社 カルボン酸型脂質並びに該カルボン酸型脂質を含んでなる脂質粒子及び脂質膜
EP3868413B1 (de) 2018-10-17 2024-07-24 Toray Industries, Inc. Hämostatisches material

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5340727A (en) 1987-11-17 1994-08-23 The Scripps Research Institute GPIbα fragments and recombinant DNA expression vectors
AU6671496A (en) * 1995-08-17 1997-03-12 Introgene B.V. Poly(organo)phosphazenes for use in synthetic transfection systems
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof

Also Published As

Publication number Publication date
AU2001236062A1 (en) 2001-09-12
DE60130741D1 (de) 2007-11-15
US20030113262A1 (en) 2003-06-19
EP1262490B1 (de) 2007-10-03
EP1262490A4 (de) 2005-06-22
WO2001064743A1 (en) 2001-09-07
DE60130741T2 (de) 2008-07-03
ES2291295T3 (es) 2008-03-01
US6926884B2 (en) 2005-08-09
EP1262490A1 (de) 2002-12-04

Similar Documents

Publication Publication Date Title
ATE374785T1 (de) Gpib-gebundenes konstrukt und verwendungen davon
Luchetti et al. Arthroscopic resection of dorsal wrist ganglia and treatment of recurrences
PT1196444E (pt) Conjugados de exendina-4 e seus usos medicos
DOP2000000114A (es) Oxazolidinonas substituidas y su uso
BR0109272A (pt) Agentes conjugados terapêuticos de ácido poliglutâmico, métodos para suas preparações e usos
EA200300845A1 (ru) Модифицированные антитела и способы применения
TR200201440T2 (tr) Biomedikal kullanım için radyum-223 hazırlanması
WO2002087563A3 (en) Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
EP1449850A4 (de) Mit humanem cdr gepfropfte antikörper und antikörperfragmente davon
CY1106886T1 (el) Πολυμερη προϊοντα συζευξης της neublastin και μεθοδοι χρησης αυτων
EP1350511A4 (de) Aspirin enthaltende medizinische zusammensetzungen
DK1392254T3 (da) Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
MA26230A1 (fr) Agents antidysrythmiques administres par voie vaginale utilises pour traiter les douleurs pelviennes et la sterilite
BR9810832B1 (pt) composição farmacêutica contendo como princìpios ativos vitamina d associada a um sal de cálcio, e, processos para a preparação de uma composição farmacêutica, para o tratamento de deficiências nutricionais de cálcio e vitamina d na velhice e para reduzir a perda de tecido ósseo ligada à idade e para evitar fraturas femurais e outras fraturas não vertebrais.
DE68925034D1 (de) Konjugate zur knochenbilddarstellung und therapie von knochenkrebs.
AR033658A1 (es) Kit de componentes, metodo para el tratamiento de la trombosis,uso de un antagonista del receptor p2t en la elaboracion de un kit de componentes para el tratamiento de la trombosis, formulacion farmaceutica, uso de la formulacion farmaceutica en la elaboracion de un medicamento para el tratamiento d
FI952593A0 (fi) Hyytymistä estävä aine
CA2433177A1 (en) Hypoallergenic and non-irritant skin care formulations
DK0383417T3 (da) Flagmusespyt-plasminogenaktivator v-PAalfa1
Crisp Mast cells in rheumatoid arthritis
ATE498305T1 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
DE60231785D1 (de) Gelierbare, biokompatible und implantierbare zusammensetzung
Samos et al. Review of the pharmacology of the emerging possibilities of the direct oral anticoagulants' reversal
GR20000100283A (el) Μη-πεπτιδικοι μιμητες της δραστικης αλληλουχιας s42fllr46 του υποδοχεα της θρομβινης για την θεραπεια της θρομβωσης και του καρκινου
Fillingham et al. Response to Letter to the Editor on" The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis"

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties